Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura
- PMID: 32914535
- PMCID: PMC7880820
- DOI: 10.1111/jth.15009
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura
Abstract
Background: Despite advances in treatment options for thrombotic thrombocytopenic purpura (TTP), there are still limited high quality data to inform clinicians regarding its management.
Methods: In June 2018, the ISTH formed a multidisciplinary guideline panel to issue recommendations about treatment of TTP. The panel discussed 12 treatment questions related to both immune-mediated TTP (iTTP) and hereditary/congenital TTP (cTTP). The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence and formulate recommendations.
Results: The panel agreed on eleven recommendations based on evidence ranging from very low to moderate certainty. For first episode and relapses of acute iTTP, the panel made a strong recommendation for the addition of corticosteroids to therapeutic plasma exchange (TPE), and a conditional recommendation for addition of rituximab and caplacizumab. For asymptomatic iTTP with low ADAMTS13, the panel made a conditional recommendation for rituximab outside of pregnancy, and for prophylactic TPE during pregnancy. For asymptomatic cTTP, the panel made a strong recommendation for prophylactic plasma infusion during pregnancy, but a conditional recommendation for plasma infusion or a wait and watch approach outside of pregnancy.
Conclusions: The panel's recommendations are based on all the available evidence for the treatment effects of various approaches including suppressing inflammation, blocking platelet clumping, replacing the missing and/or inhibited ADAMTS13, and suppressing ADAMTS13 antibody production. There was insufficient evidence for further comparison of different treatment approaches, for which future high-quality studies in iTTP (e.g., rituximab, corticosteroids, recombinant ADAMTS13, and caplacizumab) and in cTTP (eg, recombinant ADAMTS13) are needed.
Keywords: TTP; diagnosis; good practice; guidelines; management.
© 2020 International Society on Thrombosis and Haemostasis.
Similar articles
-
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914526 Free PMC article.
-
2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.J Thromb Haemost. 2025 Jun 17:S1538-7836(25)00360-5. doi: 10.1016/j.jtha.2025.06.002. Online ahead of print. J Thromb Haemost. 2025. PMID: 40533296
-
Immune Thrombotic Thrombocytopenic Purpura: A Review.JAMA. 2025 Aug 12;334(6):517-529. doi: 10.1001/jama.2025.3807. JAMA. 2025. PMID: 40388146 Review.
-
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914582 Free PMC article.
-
Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.Intensive Care Med. 2025 Jul;51(7):1225-1239. doi: 10.1007/s00134-025-07981-3. Epub 2025 Jul 3. Intensive Care Med. 2025. PMID: 40608084 Review.
Cited by
-
Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions.Ther Clin Risk Manag. 2021 Jun 3;17:577-587. doi: 10.2147/TCRM.S205632. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 34113115 Free PMC article. Review.
-
Practical Considerations for the Use of the Rapid AcuStar® ADAMTS13 Activity Assay in the Diagnosis of Acute Thrombotic Thrombocytopenic Purpura (TTP).J Clin Med. 2024 Jul 30;13(15):4462. doi: 10.3390/jcm13154462. J Clin Med. 2024. PMID: 39124729 Free PMC article.
-
A Case of Thrombotic Thrombocytopenic Purpura and ST-Elevation Myocardial Infarction: An Unusual Correlation.Cureus. 2023 Mar 12;15(3):e36039. doi: 10.7759/cureus.36039. eCollection 2023 Mar. Cureus. 2023. PMID: 37056547 Free PMC article.
-
Preferences of Patients With cTTP and Other Chronic Conditions for At-Home Prophylactic Infusions: A Discrete Choice Experiment.J Patient Exp. 2025 Jul 7;12:23743735251342135. doi: 10.1177/23743735251342135. eCollection 2025. J Patient Exp. 2025. PMID: 40630739 Free PMC article.
-
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11. J Thromb Haemost. 2020. PMID: 32914526 Free PMC article.
References
-
- Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–397. - PubMed
-
- Bell WR, Braine HG, Ness PM, Kickler TS. Improved Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403. - PubMed
-
- Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836–2846. - PubMed